Breaking News

Proteomics, inVentiv In Biosimilar Services Pact

By Kristin Brooks | March 3, 2014

Aims to streamline the development process

Proteomics International and inVentiv Health Clinical have entered a collaboration agreement to offer full service biosimilar services on a global scale from structural and functional characterization to development of biosimilars and biologics. The collaboration aims to offer developers the ability to seamlessly transition from characterization to clinical trials.
Proteomics provides structural characterization and QC testing of proposed and referenced products with a suite of scientific instrumentation. These services will complement inVentiv Health’s bioanalytical capabilities from clinical development through commercialization in support of biosimilar development.
“We welcome the partnership with inVentiv as it represents a significant opportunity for us in furthering expansion into bio-generic markets,” said Dr. Richard Lipscombe, managing director of Proteomics International. “This collaboration will position both companies to better assist biosimilar and biologics developers in this emerging field and ever-changing regulatory environment.”
“The strengths of Proteomic International to demonstrate biosimilarity combined with inVentiv biologic clinical, commercial and consulting expertise is a winning solution for clients,” said Dr. George Scott, vice president, Bioanalytical Services for inVentiv Clinical. “Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct, and registration to commercialization.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials